Fremanezumab Managed Access Program for Pediatric Patients
ConditionMigraine
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age6-17
SponsorTeva Branded Pharmaceutical Products R&D LLC
About this trial
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).
Eligibility criteria
Qualifiers
Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures
In the opinion of your physician/investigator are able to continue IMP (fremanezumab) in a safe and compliant way.
Disqualifiers
Additional criteria may apply, please contact your physician/investigator for more information.
Trial design
Treatments tested in this trial
- Fremanezumab
Treatment groups
No treatment groups listed
Locations
Sponsors and collaborators
Source ClinicalTrials.gov